Skip to main
ZYME

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks is a promising company with a positive outlook due to its strong drug development engine, deep preclinical pipeline in oncology and other therapeutic areas, and clinical candidate zanidatamab showing promising results in multiple Phase 1, Phase 2, and pivotal trials. With upcoming value inflection points, including potential FDA approval for Ziihera-based combinations and a second interim analysis for the combination of Ziihera, Tevimbra, and chemotherapy, there is potential for significant growth in the company's revenue and earnings in the future. However, there are risks associated with clinical trial failures and financing, and investors should monitor these factors closely.

Bears say

Zymeworks is a clinical-stage biopharmaceutical company with a negative outlook due to several factors. These include a reliance on a single product, YUPELRI, and potential commercial and regulatory risks associated with it. Additionally, the company faces the possibility of delays or setbacks in the development of its other pipeline products, which may impact its ability to generate revenue in the future. Moreover, there is a potential for dilution risk and partnership risks, along with uncertainties surrounding the success of its clinical trials and market uptake of its products.

Zymeworks Inc (ZYME) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Buy based on their latest research and market trends.

According to 9 analysts, Zymeworks Inc (ZYME) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.